https://www.selleckchem.com/products/abt-199.html
Elagolix is an oral, gonadotropin-releasing hormone (GnRH) receptor antagonist, that significantly reduces dysmenorrhea and non-menstrual pelvic pain (NMPP) in women with moderate to severe endometriosis-associated pain. Data were pooled from two 6-month, placebo-controlled, phase 3 studies (Elaris Endometriosis [EM]-I and II) in which 2 doses of elagolix were evaluated (150mg once daily and 200mg twice daily). Pooled data from 1600 women, aged 18-49, were used to evaluate the efficacy of elagolix and health-related quality of life
Like
Comment
Share
